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The type 2C Ser/Thr phosphatase PP2Cg
is a pre-mRNA splicing factor
Michael V. Murray, Ryuji Kobayashi, and Adrian R. Krainer1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA
To identify activities involved in human pre-mRNA splicing, we have developed a procedure to separate HeLa
cell nuclear extract into five complementing fractions. An activity called SCF1 was purified from one of these
fractions by assaying for reconstitution of splicing in the presence of the remaining four fractions. A
component of SCF1 is shown to be PP2Cg, a type 2C Ser/Thr phosphatase of previously unknown function.
Previous work suggested that dephosphorylation of splicing factors may be important for catalysis after
spliceosome assembly, although the identities of the specific phosphatases involved remain unclear. Here we
show that human PP2Cg is physically associated with the spliceosome in vitro throughout the splicing
reaction, but is first required during the early stages of spliceosome assembly for efficient formation of the A
complex. The phosphatase activity is required for the splicing function of PP2Cg, as an active site mutant
does not support spliceosome assembly. The requirement for PP2Cg is highly specific, as the closely related
phosphatase PP2Ca cannot substitute for PP2Cg. Consistent with a role in splicing, PP2Cg localizes to the
nucleus in vivo. We conclude that at least one specific dephosphorylation event catalyzed by PP2Cg is
required for formation of the spliceosome.
[Key Words: PP2Cg; phosphatase; splicing; pre-mRNA processing; spliceosome]
Received November 3, 1998; revised version accepted November 18, 1998.
Pre-mRNA splicing is a complex reaction that requires
five small nuclear ribonucleoprotein particles (snRNPs)
and numerous non-snRNP protein factors that assemble
into a spliceosome (for review, see Kra¨mer 1996; Will
and Lu¨hrmann 1997). Spliceosome assembly is an or-
dered process that involves sequential formation of com-
plexes E fi A fi B fi C (for review, see Reed and Palan-
djian 1997). The E, A, and B complexes are precursors to
the spliceosome, and the C complex is the functional
spliceosome.
A large number of components required for mamma-
lian splicing have yet to be identified. One successful
method to identify factors is complementation of either
fractionated or deficient extracts. An important advan-
tage of this approach is that the complementation assay
used to isolate a factor can also be used for further
mechanistic studies. For example, the human protein
SF2/ASF was purified as an essential factor that comple-
ments splicing in an inactive cytoplasmic S100 extract
(Krainer et al. 1990). SF2/ASF has since been shown to be
a member of a family of structurally and functionally
related splicing factors, the SR proteins, named after a
domain rich in arginine and serine dipeptides (for review,
see Fu 1995). SR proteins have multiple functions in
splicing, and the S100 complementation assay was an
important tool in determining these functions. Three
other factors were identified by fractionation of nuclear
extracts: SF1 (Kra¨mer 1992), SF3a, and SF3b (Brosi et al.
1993). SF1, also called mBBP, is involved in branch site
recognition (Berglund et al. 1997), and SF3a and SF3b
participate in the binding of U2 snRNP to the branch site
(Gozani et al. 1996).
In this work we describe a new procedure for separat-
ing HeLa nuclear extract into five complementing frac-
tions that are competent for in vitro splicing when com-
bined. By use of four of these crude fractions for bio-
chemical complementation assays, an activity in the
remaining fraction has been identified and named SCF1
(Splicing Complementing Factor 1). Purification and
characterization of this activity showed that a compo-
nent of SCF1 is the type 2C Ser/Thr protein phosphatase
PP2Cg (Travis and Welsh 1997).
Ser/Thr phosphatases can be divided into four major
classes (PP1, PP2A, PP2B, and PP2C) on the basis of their
substrate specificity, metal ion requirements, and inhibi-
tor sensitivity (for review, see Shenolikar 1994). Type 2C
phosphatases require metal ions for activity and are re-
sistant to okadaic acid, an inhibitor of the PP1 and PP2A
enzymes. Previous studies with phosphatase inhibitors
showed that type 1 and type 2A activities are required for
splicing in vitro (Mermoud et al. 1992; Tazi et al. 1992).
However, type 1 and type 2A phosphatases are a highly
diverse group, as multiple catalytic and regulatory sub-
units can associate with one another to dictate substrate
specificity (Shenolikar 1994). Which specific forms of
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these phosphatases are involved in splicing is not
known. The role of type 2C Ser/Thr protein phosphata-
ses was not addressed, as specific inhibitors are not avail-
able. The protein phosphatase PP1 has also been shown
to affect alternative splice-site choice (Cardinali et al.
1994) and the subnuclear localization of splicing factors
(Misteli and Spector 1996).
Multiple cycles of phosphorylation and dephosphory-
lation may be required for splicing. A number of mam-
malian kinases have been implicated in splicing, includ-
ing SRPK1 and SRPK2 (Gui et al. 1994; Kuroyanagi et al.
1998; Wang et al. 1998b), Clk/Sty (Colwill et al. 1996),
DNA topoisomerase I (Rossi et al. 1996), a CaMK II-like
kinase (Parker and Steitz 1997), and cyclin E–cdk2 (Seg-
hezzi et al. 1998). In vitro, most of these kinases phos-
phorylate the carboxy-terminal RS domains of SR pro-
teins, which are extensively phosphorylated in vivo (for
review, see Fu 1995). Phosphorylation of the RS domain
appears to be required for some functions of SR proteins
(Mermoud et al. 1994; Roscigno and Garcia-Blanco 1995;
Cao et al. 1997; Tacke et al. 1997; Xiao and Manley 1997)
and for their localization (Misteli and Spector 1998). In
addition, experiments with thiophosphorylated U1-70K
protein and SF2/ASF suggested that a specific dephos-
phorylation event(s) is required for splicing (Tazi et al.
1993; Cao et al. 1997). Although these studies have es-
tablished that phosphorylation and dephosphorylation
are important for splicing, the specific substrates and
enzymes involved, as well as the mechanistic conse-
quences of these modifications, are poorly understood.
Results
Establishment of a reconstituted system
Selective precipitation by ammonium sulfate was cho-
sen as a first step in fractionating nuclear extract into
complementing fractions. Two fractions were generated
at a given ammonium sulfate concentration, and the cor-
responding high and low ammonium sulfate fractions
were tested for splicing activity with b-globin pre-
mRNA. The low ammonium sulfate fraction did not
have significant splicing activity, unless the correspond-
ing high ammonium sulfate fraction was added (Fig. 1, cf.
lanes 1 and 3, 4 and 6, 7 and 9). As SR proteins are soluble
in high concentrations of ammonium sulfate (Krainer et
al. 1990; Zahler et al. 1992), the activity present in the
high ammonium sulfate fraction could be due to SR pro-
teins. To test this possibility, purified SR proteins were
added to the low ammonium sulfate fractions and splic-
ing activity was assayed. SR proteins were able to
complement the 20%–45% and 20%–50% saturation
fractions (lanes 7 and 11) but not the 20%–40% fraction
(lane 3). This result shows that the 40%–90% ammo-
nium sulfate fraction contains one or more splicing fac-
tors, in addition to SR proteins, which are needed to
complement the 20%–40% fraction. Therefore, to purify
the activity present in the high ammonium sulfate frac-
tion, the 20%–40% cut was chosen as a complementing
fraction. Further characterization showed that the 20%–
40% fraction contained the vast majority of the abun-
dant spliceosomal snRNPs (data not shown). The initial
0%–20% step removed large aggregates and improved
the signal-to-background ratio in the splicing reaction
(data not shown).
To assay for factors in the high ammonium sulfate
fraction other than SR proteins, splicing assays were car-
ried out in the presence of the 20%–40% fraction and
purified SR proteins. In addition, purified human cre-
atine kinase was added to ensure that ATP levels re-
mained constant in the splicing reactions throughout the
fractionation procedure. To purify the high ammonium
sulfate activity, we found it necessary to separate this
fraction on a CsCl equilibrium density gradient (Fig. 2A).
This step served multiple purposes. First, nucleic acids
sediment at the bottom of the gradient, whereas proteins
remain near the top. The removal of nucleic acids im-
proved the subsequent ion-exchange chromatography
step. Second, an enrichment of splicing activity was ob-
Figure 1. Fractionation of nuclear extract and reconstitution
by ammonium sulfate precipitation. Nuclear extract was frac-
tionated into high and low ammonium sulfate fractions, which
were tested alone or in combination for pre-mRNA splicing.
b-globin pre-mRNA was incubated with the indicated fractions
for 2 hr. Three sets of fractionation experiments are shown,
representing three different cuts, 20%–40%, 20%–45%, and
20%–50% saturation. Either purified HeLa SR proteins or the
corresponding high ammonium sulfate cut was added to each of
these fractions. The positions of the pre-mRNA, mRNA, lariat–
exon 2, lariat intron, and debranched intron are shown.
Murray et al.
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tained. By Bradford assay, the majority of the protein was
found in the top five fractions, whereas splicing activity
was found in fractions 4–9. Under these conditions,
some separation of proteins was obtained, as SDS-PAGE
confirmed that the protein distribution is not uniform
throughout the upper ten fractions (data not shown). Fi-
nally, a splicing inhibitor was detected in the top three to
four fractions, as assayed by inhibition of b-globin splic-
ing on addition to nuclear extract (data not shown). The
identity of this inhibitor is presently unknown. Removal
of the inhibitory activity and nucleic acid greatly aided
further purification of the high ammonium sulfate activ-
ity.
Pooled CsCl fractions were loaded onto a Poros 20 HQ
column, and the bound proteins were eluted by stepwise
salt washes (Fig. 2B). Three of the four fractions (HQFT,
HQ1M, and HQ2M) were required to reconstitute effi-
cient splicing. The HQFT plus the HQ1M fractions were
unable to complement the 20%–40% fraction plus SR
proteins for splicing activity. If, in addition to the HQFT
and HQ1M fractions, the HQ2M fraction was also in-
cluded, splicing activity was restored (Fig. 2C). In this
complementation assay, the most abundant RNA spe-
cies are lariat–exon 2 and free exon 1 from the first cata-
lytic step of splicing, perhaps because a factor required
for the second step of splicing was partially depleted. The
HQ2M fraction had <2% of the total protein recovered
and had the lowest protein complexity by SDS-PAGE
compared with the other HQ fractions (Fig. 2D). There-
fore, the activity in this fraction, named SCF1, was cho-
sen for further purification.
At this point in the procedure, five complementing
fractions from nuclear extracts have been generated:
20%–40% ammonium sulfate, SR proteins, HQFT,
HQ1M, and HQ2M (SCF1). In summary, the HQ2M frac-
tion defines an activity required for in vitro splicing,
called SCF1, which can be assayed in a reconstituted
system containing the other four complementing frac-
tions.
Purification of SCF1
SCF1 was further purified from the HQ2M fraction, as
shown in Figure 2B. By gel-filtration chromatography,
SCF1 eluted at an apparent native molecular mass of 150
kD (data not shown). The pool from this step was sepa-
rated into multiple peaks by hydrophobic interaction
chromatography (Fig. 3A). A peak of SCF1 was detected
in fraction 29, trailing into fractions 30–31 and, to a
lesser extent, fractions 32–33 (Fig. 3B). Three major pro-
tein bands, of 76, 40, and 20 kD, and four minor bands, of
48, 30, 25, and 23 kD, cochromatographed with splicing
activity (Fig. 3C). Fractions 29 and 30 were combined,
and peptide sequence was obtained individually for all
seven bands. All of the sequenced peptides belong to a
single protein, the type 2C Ser/Thr phosphatase PP2Cg
(Travis and Welsh 1997). No other bands cochromato-
graphed with SCF1 activity, although some bands trailed
into the active fractions. The multiple bands of PP2Cg
resulted from proteolytic cleavages during purification,
which apparently did not lead to dissociation of the re-
sulting fragments. In a later purification of SCF1, in
which protease inhibitor concentrations were increased
and the slow gel-filtration step was omitted, only a 76-
kD band was observed to cochromatograph with SCF1
(data not shown). However, the data in Figure 3C corre-
spond to the actual fractions used to determine the pep-
tide sequences.
PP2Cg
Type 2C phosphatases share sequence homology, which
was the basis for the identification of PP2Cg from the
Figure 2. Separation of the high ammonium sulfate fraction.
(A) CsCl equilibrium density centrifugation of the high ammo-
nium sulfate fraction. Fractions from the gradient were assayed
for splicing activity with b-globin pre-mRNA in reactions that
also contained the low ammonium sulfate fraction (20%–40%)
and SR proteins. The sedimentation of bulk protein and nucleic
acid are indicated. (B) Flow chart of SCF1 purification. (C) Frac-
tions from the Poros 20 HQ step were assayed for splicing in
combination with the 20%–40% fraction and SR proteins. In
this assay, none of the HQ fractions had complementing activ-
ity in isolation (data not shown). (D) Coomassie-stained SDS gel
of pooled fractions from the flow-through (FT) and the salt elu-
ates of the Poros 20 HQ step.
2C Ser/Thr phosphatase is a splicing factor
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human EST database (Travis and Welsh 1997). As shown
in Figure 4, PP2Cg shares significant homology in the
amino- and carboxy-terminal thirds with other type 2C
phosphatases, including PP2Ca, whose crystal structure
has been solved (Das et al. 1996). PP2Ca is a metalloen-
zyme, and the specific amino acids shown to coordinate
two Mn2+ ions in the active site of PP2Ca are also con-
served in PP2Cg, as well in other PP2C phosphatases. A
unique feature of PP2Cg is a region of ~ 200 amino acids
rich in acidic residues, which interrupts the conserved
PP2C phosphatase domains. A predicted ORF from Cae-
norhabditis elegans encoding a PP2C phosphatase also
Figure 3. Hydrophobic interaction chromatography. (A) Column profile. SCF1 from the Sephacryl S-300 chromatography step was
loaded onto a Poros 20 PH column equilibrated in high salt, and the proteins were eluted by a reverse salt gradient. The A280 and
conductivity tracing are shown. The splicing activity detected in B is indicated. (B) Splicing activity with b-globin pre-mRNA.
Fractions from the gradient and flow-through were assayed in a reaction that contained 20%–40% fraction, SR proteins, HQ1M, and
HQFT fractions. As the concentration of protein in the fractions is very low, activity is weaker than in previous steps. (C) Fractions
at or flanking the peak of splicing activity were analyzed on a 10% SDS–polyacrylamide gel stained with a fluorescent protein stain,
Sypro Orange (Molecular Probes). (*) Bands that comigrated with splicing activity.
Figure 4. Homology of PP2Cg with other
2C Ser/Thr phosphatases. The amino acid
sequence of human PP2Cg (GenBank acces-
sion no. Y13936) was compared with those
of human PP2Ca (S87759), S. cerevisiae
PTC3 (U72346), and an ORF from C. el-
egans (U00051) by the PILEUP program
(GCG) and manual adjustment. Identities
are indicated by black shading and similari-
ties by gray shading. PP2Cg has an acidic
domain from residues 117–319, and a simi-
lar domain is found in the C. elegans ORF.
In this region, homology is not indicated,
but the acidic residues are boxed. The crys-
tal structure of PP2Ca showed that six
highly conserved amino acids are involved
in coordinating two active site metal ions.
(d) Five of the six residues involved in metal
ion coordination; (l) the sixth residue,
Asp496, which was mutated to Ala to make
the active site mutant D496A.
Murray et al.
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has an acidic domain at the same position (Fig. 4). It is
not clear that these acidic domains have equivalent func-
tions, because they only show 27% identity and 35%
similarity, compared with 44% and 60% identity for the
flanking amino- and carboxy-terminal domains, respec-
tively. However, the conservation of the position, com-
position, and size of the acidic domains suggests that
these two proteins are orthologs.
Copurification of PP2C activity with SCF1
If PP2Cg were simply a contaminant in the fractions of
the Poros 20 PH column, then it would be likely to par-
tially separate from splicing activity at some other point
in the purification. A bovine ortholog of PP2Cg, called
MCPP, was detected in brain homogenates by assaying
for a phosphatase that requires Mn2+ or Mg2+, is resistant
to okadaic acid, and is inhibited by Ca2+ (Wang et al.
1995). We used the same assay conditions with myelin
basic protein (MBP) to follow this activity in fractions
generated during purification of human SCF1. Under
these conditions, type 1, 2A, and 2B phosphatase activi-
ties are not measured. Type 2C activity cofractionated
with SCF1 splicing activity during the initial ammo-
nium sulfate fractionation (data not shown), the CsCl
step (Fig. 5A,B), and the Poros 20 HQ separation (Fig. 5C).
The precise copurification of type 2C phosphatase activ-
ity with SCF1 over multiple steps strongly suggests that
PP2Cg is not a contaminant in the final purification
step.
Splicing activity of recombinant PP2Cg
Recombinant forms of PP2Cg were expressed in Esche-
richia coli or baculovirus-infected Sf9 cells as soluble
proteins, and were purified to homogeneity (Fig. 6A).
Both the E. coli and Sf9-derived rPP2Cg had phosphatase
activity (Fig. 6B). A mutant of rPP2Cg was also prepared,
with an active-site mutation, D496A, on the basis of the
crystal structure of PP2Ca, a related phosphatase (Das et
al. 1996). This substitution is predicted to disrupt the
coordination of one of two active-site metal ions. The
mutation reduced the specific activity of rPP2Cg for
phosphorylated MBP by 1500-fold (Fig. 6B). These pro-
teins were tested for activity in splicing by use of two
different assays.
Recombinant proteins were tested in an in vitro splic-
ing assay that demands that catalysis occur. When all of
the complementing fractions except the HQ2M fraction
were added to a splicing reaction, only a very low level of
splicing was observed. On addition of the HQ2M frac-
tion, which defines SCF1 activity, splicing was restored
(Fig. 6C). When rPP2Cg from Sf9 cells was added to this
assay in place of the HQ2M fraction, a weak but detect-
able increase in splicing was observed (Fig. 6, cf. lane 1
with lanes 4–9), although it was considerably less than
observed with the HQ2M fraction (Fig. 6, cf. lanes 2–3
with 4–9). However, the Poros 20 PH fractions from the
final step of SCF1 purification also had weak activity (see
Fig. 3B). Mutant rPP2Cg did not have any detectable
splicing activity (data not shown). Adding less rPP2Cg
than shown did not increase the amount of splicing ob-
served, and preincubation of rPP2Cg in nuclear extract
did not improve the splicing activity (data not shown).
These results suggest that either another factor in addi-
tion to PP2Cg, or a modification of PP2Cg, is required for
the level of activity seen in the HQ2M fraction. An in-
hibitory effect on splicing was observed at high levels of
rPP2Cg, which may be due to nonspecific effects (e.g.,
nonspecific dephosphorylation of splicing factors).
To further characterize SCF1, the requirement for spli-
ceosome assembly was investigated. Splicing reactions
containing either nuclear extract or the complementing
fractions were analyzed by native gel electrophoresis
(Konarska 1989). In whole nuclear extract, the A, B, and
C splicing complexes were resolved (Fig. 6D, lane 17).
The A and B complexes are prespliceosomal complexes,
whereas the C complex is the functional spliceosome
(for review, see Reed and Palandjian 1997). With comple-
menting fractions, but without the HQ2M fraction, only
a small amount of A complex formation was observed,
which was greatly stimulated on addition of the HQ2M
Figure 5. Copurification of type 2C phosphatase activity with
splicing activity. (A) Fractions from the upper half of a CsCl
gradient were assayed for splicing activity with b-globin pre-
mRNA in reactions that also contained the low ammonium
sulfate fraction (20%–40%) and SR proteins. (B) The same frac-
tions were assayed for type 2C phosphatase activity by incubat-
ing with 32P-labeled MBP. (C) Type 2C phosphatase activity in
fractions from the HQ column step.
2C Ser/Thr phosphatase is a splicing factor
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fraction (lanes 1–4). Stimulation of B complex was also
observed, whereas detectable C complex did not accu-
mulate. These data show that SCF1 is required for effi-
cient A complex formation.
To determine whether the A complex stimulation by
SCF1 is due to PP2Cg, recombinant proteins were tested
in the spliceosome assembly assay. rPP2Cg had full
SCF1 activity in this assay, and recombinant proteins
expressed in Sf9 cells or E. coli showed equivalent ac-
tivities (Fig. 6D, lanes 5–10). Any additional factor or
modification of PP2Cg required for splicing catalysis is
not required for A complex, and probably B complex,
assembly. The catalytically inactive form of rPP2Cg,
D496A, was unable to substitute for SCF1 (lanes 11–13),
showing that phosphatase activity is required. Another
type 2C phosphatase was tested for SCF1 activity in the
complex assembly assay. PP2Ca is homologous to
PP2Cg, except that it lacks an acidic domain (Fig. 4).
Although related at the sequence and biochemical level,
PP2Ca was unable to stimulate A complex formation,
and was actually somewhat inhibitory (Fig. 6D, lanes
14–16). As this protein has in vitro phosphatase activity
with MBP (Fig. 6B), phosphatase activity alone is not
sufficient for SCF1 activity. In addition, PP1 and PP2A
activities are not required for A complex assembly (Mer-
moud et al. 1992; Tazi et al. 1992). We conclude that the
A complex formation activity of SCF1 can be fully ac-
counted for by PP2Cg, requires phosphatase activity, and
is specific for PP2Cg.
Association of PP2Cg with the spliceosome
Monoclonal antibodies were raised to recombinant
PP2Cg. A Western blot of HeLa nuclear extract probed
with three different monoclonal antibodies detected a
single band of 76 kD (Fig. 7A). This size is consistent
with the observed mobility of rPP2Cg and the reported
mobilities of bovine and mouse PP2Cg (Wang et al. 1995;
Guthridge et al. 1997). Although the antibodies recog-
nized at least some of the proteolytic fragments in puri-
fied preparations of PP2Cg (data not shown), only the
full-length protein was detected in nuclear extract, con-
firming that the multiple bands observed in the final
purification of SCF1 (Fig. 3C) arose from proteolysis dur-
ing purification.
To determine whether PP2Cg is physically associated
with the spliceosome, immunoprecipitations were car-
ried out from in vitro splicing reactions containing ra-
diolabeled pre-mRNA. RNA was recovered from the im-
munoprecipitates and analyzed by denaturing PAGE.
The anti-PP2Cg monoclonal antibody efficiently immu-
noprecipitated the precursor, intermediates, and prod-
ucts of splicing, showing that PP2Cg is stably associated
with the spliceosome at multiple steps (Fig. 7B). The
amount of RNA in the anti-PP2Cg immunoprecipitate is
comparable with that of two control antibodies against
snRNPs (Sm and trimethyl G). As a negative control, a
monoclonal antibody directed against E. coli maltose-
binding protein (MalE) was used, and in this case no ra-
diolabeled RNAs were immunoprecipitated. This experi-
ment does not reveal whether the interaction between
PP2Cg and RNA is direct or indirect. UV-cross-linking/
immunoprecipitation experiments did not reveal a direct
association of PP2Cg with RNA (data not shown).
Subcellular localization of PP2Cg
If PP2Cg is involved in splicing in vivo, then at least
Figure 6. Phosphatase and splicing activity of recombinant PP2Cg. (A) Coomassie-stained SDS gel of recombinant proteins. Mutant
PP2Cg has an alanine substitution for a highly conserved aspartate at position 496 (D496A). (B) Specific phosphatase activity of
recombinant protein with 32P-labeled MBP as a substrate. The D496A mutation results in a nearly inactive form of the phosphatase.
(C) rPP2Cg was assayed for splicing with b-globin pre-mRNA in a reaction that contained the 20%–40% fraction, SR proteins, and
HQFT and HQ1M fractions. Lanes 2 and 3 contain 1 and 2 µl, respectively, of the HQ2M fraction, which contains 0.1 U/µl of
phosphatase activity (1 unit = 1 nmole/min). rPP2Cg was added in lane 4 (50 ng, 0.02 unit), lane 5 (100 ng), lane 6 (200 ng), lane 7 (500
ng), lane 8 (1000 ng), and lane 9 (2000 ng). (D) Native gel analysis of spliceosomal complexes formed on b-globin pre-mRNA. The
indicated combinations of fractions were incubated for 1 hr under splicing conditions and analyzed by native gel electrophoresis.
Reactions contained either 0.4, 1, and 2 µl of the HQ2M fraction or 20, 50, and 100 ng of the indicated recombinant proteins. As a
control, the complexes formed in a 30-min incubation with nuclear extract are also shown.
Murray et al.
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some of it should be localized to the nucleus. The intra-
cellular localization of endogenous PP2Cg was deter-
mined by indirect immunofluorescence with anti-PP2Cg
monoclonal antibodies (Fig. 7C). PP2Cg localized to the
nucleoplasm and was excluded from the nucleolus. No
staining was detectable in the cytoplasm. All three anti-
PP2Cg monoclonal antibodies gave the same pattern
(data not shown). The nucleoplasmic localization is con-
sistent with a role in pre-mRNA splicing, but is in con-
trast to the speckle pattern observed for a number of
other splicing factors, such as SC35 (Fu and Maniatis
1990). On the other hand, the splicing factor U1-70K and
some hnRNP proteins that have been implicated in
splicing give a staining pattern similar to that observed
for PP2Cg (Misteli and Spector 1998). A similar localiza-
tion was reported for an epitope-tagged version of a trun-
cated form of mouse PP2Cg lacking the first 150 amino
acids (Guthridge et al. 1997).
Discussion
SCF1 is a new pre-mRNA splicing activity, defined as
one of five complementing fractions derived from HeLa
nuclear extract. SCF1 was purified, and one of its com-
ponents is the Ser/Thr phosphatase PP2Cg. Monoclonal
antibodies were used to show that PP2Cg is a nuclear
phosphatase and is physically associated with the spli-
ceosome in vitro. SCF1 is required for efficient A com-
plex assembly, an early event in the splicing pathway.
The spliceosome assembly activity is clearly attributable
to PP2Cg, as recombinant PP2Cg can fully substitute for
a partially purified fraction that defines SCF1.
Although SCF1 is required for the first step of splicing,
recombinant PP2Cg only weakly promoted catalysis
when substituted for a more active, partially purified
SCF1 fraction. Therefore, full activity in splicing cataly-
sis must require another component, in addition to
PP2Cg, or a necessary modification of PP2Cg is lacking
in the recombinant protein. We cannot presently distin-
guish between these possibilities. This presumptive fac-
tor or modification is not required for A complex assem-
bly, but it is required at a later step prior to, or coinciding
with, the catalytic steps of splicing. If a factor in addition
to PP2Cg is required for catalysis, then it is likely that
such a factor was only partially separated from PP2Cg at
the final purification step but did not cochromatograph
with SCF1. We attempted to remove PP2Cg from
nuclear extract by immunodepletion. Although exten-
sive depletion could be obtained, as determined by West-
ern blotting, no effect on splicing was observed (data not
shown). However, complete removal of a catalytic activ-
ity from an extract is difficult, and a low level of PP2Cg
may be sufficient for splicing.
PP2Cg and other type 2C Ser/Thr protein phosphatases
The PP2C family is a diverse group of proteins, and type
2C phosphatases contain additional motifs such as EF
hands, kinase-interacting, and membrane-spanning do-
mains (see Das et al. 1996). Consistent with this struc-
tural diversity, type 2C phosphatases have been shown
to be involved in diverse biological processes in both
prokaryotes and eukaryotes. In mammals, two other
PP2C enzymes have been identified, PP2Ca and PP2Cb,
which lack discernible motifs other than the PP2C ho-
mology (Tamura et al. 1989; Mann et al. 1992; Wenk et
al. 1992). Although these two phosphatases have been
characterized biochemically (e.g., see Marley et al. 1996;
Kusuda et al. 1998), little is known about their roles in
biological processes. There is evidence that PP2Ca nega-
tively regulates the JNK MAPK pathway (Takekawa et
al. 1998), the activity of the cystic fibrosis transmem-
brane conductance regulator (Travis et al. 1997), and the
AMP-activated protein kinase (Moore et al. 1991; Davies
et al. 1995).
Mammalian PP2Cg differs from other type 2C phos-
phatases by the presence of a large internal domain of
acidic character. Characterization of bovine PP2Cg
showed that the substrate specificity in vitro is broad but
that it has a preference for basic proteins (Wang et al.
1995). This preference suggests that electrostatic inter-
actions mediated by the acidic domain may be involved
in substrate specificity. The mouse ortholog of PP2Cg,
Figure 7. Association of PP2Cg with the spliceosome and in-
tracellular localization. (A) Western blot of HeLa nuclear extract
probed with three different anti-PP2Cg monoclonal antibodies.
(B) Immunoprecipitations of b-globin splicing reactions after a
1-hr incubation. Radiolabeled RNA was recovered from the im-
munoprecipitates and analyzed by denaturing PAGE. The
amount of input RNA shown is equivalent to 10% of the
amount used for each immunoprecipitation. Anti-Sm (mAb
Y12) and anti-trimethyl guanosine (mAb K121) immunoprecipi-
tations were included as positive controls, and an anti-maltose-
binding protein (a-MalE) antibody (mAb105) served as a nega-
tive control. (C) The intracellular localization of PP2Cg in HeLa
cells was determined by use of an anti-PP2Cg monoclonal an-
tibody (7-53) and FITC-conjugated secondary antibody. SC35
localization is included as a positive control and as a marker for
the speckle region of the nucleus.
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called FIN13, was identified in a screen for cDNAs in-
duced by the fibroblast growth factor FGF-4 (Guthridge
et al. 1996). Interestingly, overexpression of FIN13 lack-
ing the first 150 amino acids causes a G1/S arrest, sug-
gesting a direct or indirect role in cell cycle control
(Guthridge et al. 1997). No obvious orthologs of PP2Cg
are present among the type 2C phosphatases in Saccha-
romyces cerevisiae, and the extensive genetic analyses of
splicing in this organism have not yet revealed a role for
phosphatases in splicing. Therefore, the requirement for
PP2Cg in mammalian splicing may reflect the more
complex aspects of fidelity and regulation of splice-site
selection, compared with budding yeast.
The role of phosphatases in splicing
PP2Cg catalyzes at least one specific dephosphorylation
event required for A complex formation during spliceo-
some assembly. In contrast, general inhibitors of PP1 and
PP2A activities block the catalytic steps of splicing, but
not assembly of the A, B, and C complexes (Mermoud et
al. 1992; Tazi et al. 1992). As the inhibitors used do not
affect type 2C phosphatases, earlier studies could not
address the role of these phosphatases in splicing. Spe-
cific inhibitors of type 2C phosphatases have not been
described, but PP2Cg is inhibited by calcium (Wang et al.
1995). The same concentration of calcium that inhibits
the phosphatase activity of PP2Cg also inhibits in vitro
splicing in unfractionated nuclear extract (data not
shown). This observation is consistent with the require-
ment for PP2Cg in splicing.
In addition to phosphatase inhibitor studies, the cata-
lytic steps of splicing, but not spliceosome assembly, are
blocked when either of two proteins, the U1 snRNP pro-
tein U1-70K and the splicing factor SF2/ASF, are made
phosphatase resistant by thiophosphorylation (Tazi et al.
1993; Cao et al. 1997). These data suggested that these
factors must be dephosphorylated after formation of the
spliceosome but before the first catalytic step. However,
this approach did not permit assignment of the dephos-
phorylation activity to a particular Ser/Thr phosphatase.
Even though PP2Cg has a role in A complex formation
early in spliceosome assembly, it may have an additional
role later in the splicing reaction. In fact, immunopre-
cipitation experiments show that PP2Cg is associated
with the spliceosome at all detectable stages, suggesting
that PP2Cg may have a function at later stages of splic-
ing.
Phosphorylation may also play a role in the regulation
of alternative splicing, which is affected by the activity
and/or levels of general splicing factors, such as SR pro-
teins and hnRNP proteins (Wang et al. 1997). Overex-
pression of the Clk/Sty kinase, which can phosphorylate
SR proteins, changes the alternative splicing of its own
pre-mRNA and of an adenovirus pre-mRNA (Duncan et
al. 1997). Addition of exogenous PP1 to nuclear extracts
changes alternative 58 splice site use in HeLa nuclear
extracts (Cardinali et al. 1994). A splicing silencer within
an adenovirus intron can be regulated by the phosphory-
lation state of SR proteins, and in adenovirus-infected
cells, SR protein phosphorylation may be controlled by
PP2A and the viral PP2A-regulatory subunit E4-ORF4
(Kanopka et al. 1998). We do not know if PP2Cg regu-
lates alternative splicing, but it is interesting that the
levels of mouse PP2Cg can be upregulated by the growth
factor FGF-4 (Guthridge et al. 1996). The levels of PP2Cg
could either modulate the intrinsic activity of a splicing
factor or affect its intracellular location, and hence its
local concentration or availability. For example, there is
evidence that phosphorylation/dephosphorylation regu-
lates the localization of splicing factors within the sub-
nuclear speckle domain (Gui et al. 1994; Colwill et al.
1996; Misteli and Spector 1996), the recruitment of SR
proteins to transcriptionally active sites (Misteli et al.
1998), and the shuttling of SR proteins (Ca´ceres et al.
1998).
Potential targets of PP2Cg
Although the targets of PP2Cg action are not presently
known, several of the known mammalian splicing fac-
tors are phosphoproteins, and hence, potential substrates
of PP2Cg. In particular, splicing factors known to be re-
quired for A complex assembly (see Reed and Palandjian
1997) are good candidates. Among these are the SR pro-
teins, which are essential splicing factors containing ser-
ine-phosphorylated carboxy-terminal repeats of argi-
nine/serine dipeptides (for review, see Fu 1995). Phos-
phorylation of SR proteins appears to be required for
splicing in vitro (Mermoud et al. 1994; Cao et al. 1997;
Xiao and Manley 1997), and in particular for recruitment
of the U4/U6 ? U5 tri-snRNP to the A complex (Roscigno
and Garcia-Blanco 1995). In addition, the interaction be-
tween another phosphoprotein, U1-70K, and the SR pro-
tein SF2/ASF, is phosphorylation dependent (Xiao and
Manley 1997). This interaction is required for stimula-
tion of U1 snRNP binding to a 58 splice site by SF2/ASF,
which occurs prior to A complex formation (Kohtz et al.
1994). However, the fact that thiophosphorylation of
SF2/ASF inhibits catalysis but not spliceosome assem-
bly (Cao et al. 1997) suggests that PP2Cg does not de-
phosphorylate SF2/ASF during A complex formation.
Another phosphorylated splicing factor required for A
complex assembly is SAP155, a component of the 17S
U2 snRNP (Wang et al. 1998a). SAP155 has homology to
PP2A regulatory subunits, and is phosphorylated after
the first catalytic step of splicing. Recently, SAP155 has
been shown to interact with the cyclin E–cdk2 kinase
(Seghezzi et al. 1998).
The physiological substrate specificity of PP2Cg is un-
likely to be solely an inherent property of its active site.
Specificity will also depend on the subcellular localiza-
tion of the enzyme, its physical association with the spli-
ceosome, and other protein–protein interactions. The
fact that PP2Ca cannot function in place of PP2Cg, de-
spite their similar biochemical properties and strong se-
quence homology, suggests that the unique acidic do-
main of PP2Cg plays a crucial role in determining sub-
strate specificity. Thus, a meaningful assessment of the
Murray et al.
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substrate specificity of PP2Cg in splicing will likely re-
quire the full context of the spliceosome.
Materials and methods
Preparation of HeLa nuclear extract and ammonium
sulfate fractionation
HeLa nuclear extracts were prepared as described (Mayeda and
Krainer 1999b). For ammonium sulfate fractionation, 2 vol of
buffer E [20 mM HEPES–KOH (pH 8), 0.2 mM EDTA, 1 mM DTT]
and 0.75 vol of buffer E-AS (saturated with ammonium sulfate
at 0°C) was added. The suspension was rocked for 30 min and
spun at 14,460gmax for 15 min. The supernatant was diluted
with 0.33 vol of buffer E-AS. The suspension was rocked for 30
min and spun as above. The pellet was resuspended in 40%
saturated ammonium sulfate in buffer E and respun for 30 min.
The pellet was redissolved in half of the volume of the starting
nuclear extract in buffer D [buffer E + 100 mM KCl, 0.5 mM
PMSF, 5% (vol/vol) glycerol] and dialyzed against buffer D. The
supernatant from the initial 40% cut was adjusted to 90% satu-
ration by the addition of dry ammonium sulfate (0.335 grams/
ml solution). The suspension was rocked for 30 min and spun
for 15 min. The pellet was redissolved in buffer D and dialyzed
against buffer D. All fractions were stored at −70°C.
Purification of SCF1
Frozen HeLa or 293 cells (100 liters) were thawed and collected
as described (Krainer et al. 1990). The washed cell pellet was
resuspended in an equal volume of buffer A + PI [10 mM HEPES–
KOH (pH 8.0), 10 mM KCl, 1.5 mM MgCl2; PI = 0.5 mM PMSF,
3.5 µg/ml pepstatin, 2.5 µg/ml leupeptin, 0.5 µg/ml aprotinin)
and incubated for 10 min on ice. Cells were lysed by 30 strokes
in a 100-ml Dounce homogenizer (B pestle) followed by the
addition of 0.078 vol of 4 M KCl. The homogenate was stirred for
20 min and spun at 4000 rpm in an H6000A rotor for 15 min.
The supernatant was diluted with 1 vol of buffer E plus 1.33 vol
of buffer E-AS, stirred for 20 min and spun at 14,680gmax for 30
min. Dry ammonium sulfate (0.335 gram/ml) was added to the
supernatant, dissolved by stirring for 30 min and spun as above.
The pellet was dissolved in buffer D + PI.
Dry CsCl was added (1 gram/ml) and dissolved by rocking. An
equal volume of this solution was layered beneath a 32-ml layer
of 30% (wt/vol) CsCl in buffer D in a Ti 45 tube and spun at
235,000gmax for 24 hr. Gradients were harvested with a gradient
fractionator (Haake-Buchler) and fractions were dialyzed against
buffer D + PI-500 (500 mM KCl). Active fractions were pooled,
diluted fivefold with buffer D + PI-0 (0 M KCl) and loaded onto a
1 × 10 cm Poros 20 HQ column on a Biocad Sprint (Perseptive
Biosystems) equilibrated in buffer D. Bound proteins were
eluted by stepwise washes of buffer D-400, buffer D-1M, and
buffer D-2M (3 column vol) at 10 ml/min. The 2 M eluate was
dialyzed against buffer D and loaded onto a 1.6 × 60-cm Sephac-
ryl S-200 HR column (Pharmacia) equilibrated in buffer D at 0.5
ml/min. Active fractions were pooled, diluted with 0.66 vol of
buffer D-AS + PI and loaded onto a 1.6 × 100-mm Poros 20 PH
column equilibrated in 40% saturated ammonium sulfate in
buffer D. A 20-column volume gradient from 40% to 0% satu-
rated ammonium sulfate in buffer D was run at 5 ml/min. Frac-
tions were dialyzed against buffer D + PI.
Splicing assays
In vitro splicing assays were done as described (Mayeda and
Krainer 1999a). To assay for SCF1, the following mixture was
prepared (amount/reaction): 2 µl of the 20%–40% ammonium
sulfate fraction, 0.05 unit of human creatine kinase (1.9 U/µl),
1 µl of purified HeLa SR proteins (0.62 mg/ml), 1 µl of HQFT, 1
µl of HQ1M. To 5 µl of this mixture, up to 4 µl of the fraction
to be assayed for SCF1 was added, the volume was adjusted to 9
µl with buffer D, and 6 µl of a splicing premix was added. The
reactions were incubated for 2 hr.
Native splicing complex assays were done as described (Ko-
narska 1989), with 0.1 mg/ml heparin.
Immunoprecipitations of splicing reactions were done as de-
scribed (Blencowe et al. 1994), except that 0.5 mg/ml tRNA was
included in the washes.
Peptide sequencing
Fractions 29 and 30 from the Poros 20 PH column were pooled
and separated by SDS-PAGE. After Coomassie G staining, the
protein bands were excised and subjected to in-gel digestion
with Lys-C endopeptidase. The resulting peptides were sepa-
rated by HPLC and sequenced by automated Edman degradation
as described previously (Wang et al. 1996).
Recombinant proteins/antibodies
PP2Cg was PCR amplified from a human EST clone (IMAGE
clone 531667, Research Genetics) using Pfu polymerase (Strata-
gene) and the primers GTGGATCCACATATGGGTGCCTAC-
CTCTC and CAGGATCCACTAGTCCCTCTTGG. The PCR
product was digested with NdeI and BamHI and subcloned into
pET-19b. The resulting E. coli expression plasmid, pNTPP2Cg,
encodes full-length PP2Cg with an amino-terminal His tag. The
mutant D496A was made from pNTPP2Cg as described (Deng
and Nickoloff 1992) with the primers GGTCATGTTGGCA-
CACCCGGTACCATCCC and CTTCCTTTTTCGATATCAT-
TGAAGCATTT. To express PP2Cg in Sf9 cells, an NcoI–
BamHI fragment from pNTPP2Cg was ligated into the NcoI–
BglII sites of the expression vector, pAcSG2. Recombinant virus
was made with a Baculogold kit (PharMingen).
To purify rPP2Cg, 1 liter of E. coli BL21 transformed with
pNTPP2Cg was induced at an OD of 0.4 by addition of 0.4 mM
IPTG and shaken at 37°C for 4 hr. Cells were harvested, washed
in PBS and lysed by sonication (5–10-sec pulses with 2-min
rests) in 30 ml of lysis buffer [20 mM HEPES–KOH (pH 8), 1 M
NaCl, 20 mM imidazole, 0.2 mM EGTA, 0.2 mM PMSF, 2 mM
MnCl2, 1 mM DTT, 5% glycerol]. The lysate was spun at
32,530gmax for 15 min. The supernatant was added to 2 ml of
NiNTA agarose (Qiagen) equilibrated in lysis buffer without
MnCl2 and rocked for 15 min. The resin was pelleted in a table
top centrifuge and washed twice with 20 vol of lysis buffer and
twice with 20 vol of lysis buffer 100 (100 mM NaCl). Bound
proteins were eluted by two washes with 1 vol of elution buffer
(lysis buffer 100 + 200 mM imidazole). The eluate was dialyzed
against buffer D and loaded onto a 1.6 × 100 mm Poros 20 HQ
column equilibrated in buffer D. A 20-column volume gradient
from 0.4 M to 1.5 M KCl in buffer D was run at 5 ml/min.
Fractions containing PP2Cg were pooled and dialyzed against
buffer D.
rPP2Cg was purified from 350 ml of baculovirus-infected Sf9
cells (~ 106/ml in T-175 flasks) as above, except for the following
modifications. Lysis and elution buffers contained protease in-
hibitors (see above) and lacked MnCl2 and EGTA. Cells were
resuspended in 5 ml of lysis buffer and sonicated five times for
5 sec with 1 min rests. Cleared lysate was added to 0.25 ml
NiNTA agarose.
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To raise monoclonal antibodies, BALB/c mice were immu-
nized with rPP2Cg from E. coli. Hybridomas were generated and
screened by dot blotting at the Cold Spring Harbor Monoclonal
Antibody Facility by standard procedures (Harlow and Lane
1988).
Phosphatase assays
Type 2C phosphatase activity was assayed as described (Wang et
al. 1995) by use of radiolabeled MBP phosphorylated with pro-
tein kinase A.
Immunofluorescence
Immunofluoresence experiments were carried out as described
(Misteli and Spector 1996).
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